ASPIVIX has announced a new partnership with AGHealth to launch Carevix, its MHRA-approved non-traumatic suction cervical stabiliser, in the United Kingdom. The company says this milestone marks a significant advance in UK women’s healthcare, offering a modern and clinically validated alternative to the traditional cervical tenaculum.
Camgenium, a leading medical device software company, has announced that its software product, ‘Reassure Pregnancy’, can improve outcomes for pregnant women at risk of pre-eclampsia through at-home monitoring.
A Caltech-led team has developed a safe, effective, and painless breast imaging technique that incorporates machine learning to help differentiate between suspicious and healthy tissue.
Inne, a healthtech startup empowering women to understand their reproductive health, has ‘broken through decades of stagnation’ in women’s health and become what it says is the first new tech-enabled contraception to receive certification in the UK and Europe with its Minilab saliva test device.
First-Ever Non-Surgical Permanent Birth Control System Gains CE Mark, Paving the Way for a New Era in Reproductive Health
Breakthrough Integrated Sacral Neuromodulation Device Approved to Treat Urinary Urge Incontinence with a Minimally Invasive, Patient-Centric Approach
Lilli Health, a company that coined the term Low Insulin Lifestyle [LILLI] created to help educate, treat and manage individuals with polycystic ovary syndrome (PCOS), has announced the launch of the Lilli App backed by decades of scientific research as the first-ever comprehensive platform focused on lowering insulin levels to reverse PCOS symptoms.
A new point of care test for pre-eclampsia is set to revolutionise testing for suspected pre-eclampsia in maternity units across the UK, aiding early detection and prognosis in pregnant women between 20-37 weeks of gestation.
SAN JOSE, Calif., June 18, 2025 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has approved its integrated sacral neuromodulation (iSNM) system for the treatment of urinary urge incontinence (UUI).
The BiophysicaL Immune Profiling for Infants (BLIPI) profiles an infant’s immune system in under 15 minutes, using just a single drop of blood.